The purpose of the Cancer Genomics Shared Resource (CGSR) is to maximize scientific and clinical impact of Atrium Health enterprise-wide research toward the discovery and characterization of genomic, transcriptomic and epigenetic alterations that:

  1. underlie cancer formation and progression,
  2. explain inter- and intra-tumoral molecular and clonal heterogeneity,
  3. predict clinical cancer behavior and treatment outcomes, and
  4. impact tumor-immune and drug-response interactions.

The CGSR achieves this mission by providing rapid and cost-effective access to state-of-the-art Next Generation DNA sequencing (NGS) technologies, expertise in clinical assay development, and interdisciplinary collaboration and education in the genomic sciences.

The CGSR prioritizes cancer-specific research, creates an optimal environment for the Institution’s rapidly developing Precision Oncology Initiative (POI), and partners with other key Shared Resources (SRs) to promote integrated cross-SR service workflows for advanced genomic applications such as single-cell and spatial single-cell expression profiling.

The Molecular Biology and Genomics Core Laboratory, which recently merged with the CGSR, is a full-service, CLIA certified facility located in the Levine Cancer Institute at Carolinas Medical Center under the direction of Nury Steuerwald, PhD, HCLD (ABB). Its mission is to develop and offer novel clinical molecular diagnostic tests in support of our clinicians and for the benefit of our patients.

Focus Areas

  • Whole genome/whole exome sequencing
  • RNA sequencing
  • Single cell RNA sequencing and multi-omic/spatial analysis
  • Nucleic acid (RNA/DNA) isolation and QC
  • Development of clinical genomic tests